Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Mercury Pharma International Ltd, 4045, Kingswood Road, City West Business Park, Co Dublin, Ireland
Digoxin 250 micrograms/ml Solution for Injection.
Pharmaceutical Form |
---|
Solution for Injection. Clear, colourless, sterile solution, intended for parenteral administration to human beings. |
Each 2ml of solution contains 500 micrograms of Digoxin.
Excipient(s) with known effect: Ethanol 96% 0.250 ml.
Also contains 2.92 mg sodium per 2ml.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Digoxin |
Digoxin increases contractility of the myocardium by direct activity. The primary action of digoxin is specifically to inhibit adenosine triphosphatase, and thus sodium-potassium (Na+ - K+) exchange activity, the altered ionic distribution across the membrane resulting in an augmented calcium ion influx and thus an increase in the availability of calcium at the time of excitation-contraction coupling. The potency of digoxin may therefore appear considerably enhanced when the extracellular potassium concentration is low, with hyperkalaemia having the opposite effect. |
List of Excipients |
---|
Ethanol |
2ml, clear One point cut (OPC) glass ampoules, glass type 1 Ph.Eur. borosilicate glass, packed in cardboard cartons to contain 10 × 2ml ampoules.
Mercury Pharma International Ltd, 4045, Kingswood Road, City West Business Park, Co Dublin, Ireland
PL 02848/5934R
24/1/91
Drug | Countries | |
---|---|---|
DIGOXIN | Nigeria |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.